In a move that marks the most significant shift in U.S. drug policy in decades, the federal government has officially reclassified cannabis from Schedule I to Schedule III. Signed by Acting Attorney General Todd Blanche, the order aligns federal law with the medical marijuana programs already operating in 40 states, including those in heavily Latino communities from Los Angeles to Miami.
Schedule I had long placed cannabis alongside heroin and LSD—substances deemed to have no medical use and a high potential for abuse. Schedule III, by contrast, acknowledges therapeutic value with moderate or low risk of dependence. This is not full legalization, but it redefines the landscape for patients, doctors, and researchers across the Americas.
What This Means for Patients and Doctors
For the first time, researchers can study cannabis without fear of federal sanctions, opening doors to rigorous clinical trials. Doctors gain clearer federal backing to recommend medical marijuana, supporting systems that have operated in states like California—where medical use was first approved in 1996—and in New York, where Latino communities have long advocated for equitable access.
State-licensed medical marijuana companies can now deduct business expenses from federal taxes, a relief that many small businesses in the sector have awaited. This financial shift could help Latino-owned dispensaries in cities like Denver and Chicago compete more fairly.
A Contrast with State Realities
Only Idaho and Kansas now prohibit cannabis entirely. Two dozen states have authorized recreational use, creating a patchwork that the federal order begins to address. The move acknowledges what many Latinos in the diaspora already know: cannabis is part of daily life, from medicinal use for chronic pain to cultural acceptance in communities across México, Puerto Rico, and beyond.
This federal change follows years of tension between local and national laws. It does not legalize recreational use, but it removes a key barrier for medical programs that serve millions, including many Latino patients who rely on cannabis for conditions like arthritis, anxiety, and chemotherapy side effects.
The Debate: Medicine or Corporate Relief?
As expected, the decision has polarized opinions. Michael Bronstein of the American Cannabis and Hemp Trade Association called it a historic breakthrough, stating that “cannabis is medicine.” But Kevin Sabet of Smart Approaches to Marijuana labeled it “tax relief for big companies,” warning about the risks of increasingly potent products.
The debate echoes broader conversations in Latino communities, where cannabis has been both a traditional remedy and a source of stigma. In cities like Bogotá and Buenos Aires, medical cannabis programs have grown, but the U.S. shift could influence policy across Latin America. Meanwhile, the government plans additional hearings in late June, and the industry watches closely.
For now, the change offers a new framework for medical access, research, and business. It does not erase decades of prohibition, but it signals a shift in perspective—one that many in the Latino world have long advocated for. As the U.S. moves forward, the impact will be felt from the clinics of Los Angeles to the farms of Oaxaca.
For more on how communities are adapting, see our coverage of Brooklyn's Linden Boulevard safety overhaul and Antonela Roccuzzo's entrepreneurial journey.
